Esperion reports positive results from ETC-1002 Phase 2 clinical trial on type 2 diabetes

Esperion Therapeutics, the leading developer of small molecule therapies for the treatment of cardiometabolic disorders, today announced positive results of a recently completed Phase 2 clinical trial of ETC-1002 in patients with type 2 diabetes with LDL-C lowering of up to 43% compared to placebo.

Read more...
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

8 Ways to Trick Yourself Thin

8 Ways to Trick Yourself Thin An article from By Chris Freytag The formula for weight loss may be simple-take in fewer calories ...